Terms: = Breast cancer AND MAP3K1, ENSG00000095015, 4214, Q13233, MEKK1, MEKK, MAPKKK1
135 results:
1. Prognostic Factors Associated with Tumor Recurrence and Overall Survival in Soft Tissue Sarcomas of the Extremities in a Colombian Reference cancer Center.
Díaz Casas SE; Villacrés JM; Lehmann Mosquera C; García Mora M; Mariño Lozano I; Ángel Aristizábal J; Suarez Rodríguez R; Duarte Torres CA; Sánchez Pedraza R
Curr Oncol; 2024 Mar; 31(4):1725-1738. PubMed ID: 38668034
[No Abstract] [Full Text] [Related]
2. Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.
Takeshita T; Iwamoto T; Niikura N; Watanabe K; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
ESMO Open; 2024 Apr; 9(4):102385. PubMed ID: 38387111
[TBL] [Abstract] [Full Text] [Related]
3. Genomic Characteristics and Its Therapeutic Implications in breast cancer Patients with Detectable Molecular Residual Disease.
Zhang S; Jiang Y; Zhou L; Xu J; Zhang G; Shen L; Xu Y
Cancer Res Treat; 2024 Apr; 56(2):538-548. PubMed ID: 38062709
[TBL] [Abstract] [Full Text] [Related]
4. Association of Germline Variation in Driver Genes with breast cancer Risk in Chilean Population.
Morales-Pison S; Tapia JC; Morales-González S; Maldonado E; Acuña M; Calaf GM; Jara L
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003265
[TBL] [Abstract] [Full Text] [Related]
5. PhenoDriver: interpretable framework for studying personalized phenotype-associated driver genes in breast cancer.
Li Y; Zhang SW; Xie MY; Zhang T
Brief Bioinform; 2023 Sep; 24(5):. PubMed ID: 37738403
[TBL] [Abstract] [Full Text] [Related]
6. Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.
Wilcox N; Dumont M; González-Neira A; Carvalho S; Joly Beauparlant C; Crotti M; Luccarini C; Soucy P; Dubois S; Nuñez-Torres R; Pita G; Gardner EJ; Dennis J; Alonso MR; Álvarez N; Baynes C; Collin-Deschesnes AC; Desjardins S; Becher H; Behrens S; Bolla MK; Castelao JE; Chang-Claude J; Cornelissen S; Dörk T; Engel C; Gago-Dominguez M; Guénel P; Hadjisavvas A; Hahnen E; Hartman M; Herráez B; ; Jung A; Keeman R; Kiechle M; Li J; Loizidou MA; Lush M; Michailidou K; Panayiotidis MI; Sim X; Teo SH; Tyrer JP; van der Kolk LE; Wahlström C; Wang Q; Perry JRB; Benitez J; Schmidt MK; Schmutzler RK; Pharoah PDP; Droit A; Dunning AM; Kvist A; Devilee P; Easton DF; Simard J
Nat Genet; 2023 Sep; 55(9):1435-1439. PubMed ID: 37592023
[TBL] [Abstract] [Full Text] [Related]
7. Efforts to Grow Genomic Research in Ancestrally Diverse and Admixed Populations.
Schmit SL; Purrington K; Figueiredo JC
Cancer Res; 2023 Aug; 83(15):2443-2444. PubMed ID: 37525976
[TBL] [Abstract] [Full Text] [Related]
8. The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.
Vellichirammal NN; Tan YD; Xiao P; Eudy J; Shats O; Kelly D; Desler M; Cowan K; Guda C
Hum Genomics; 2023 Jul; 17(1):64. PubMed ID: 37454130
[TBL] [Abstract] [Full Text] [Related]
9. Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Guo S; Jin F; Zheng A
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37283514
[TBL] [Abstract] [Full Text] [Related]
10. map3k1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer.
Kuo SH; Wei MF; Lee YH; Lin JC; Yang WC; Yang SY; Huang CS
Cell Oncol (Dordr); 2023 Oct; 46(5):1213-1234. PubMed ID: 37166744
[TBL] [Abstract] [Full Text] [Related]
11. Profiling the Somatic Mutational Landscape of breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.
Ding YC; Song H; Adamson AW; Schmolze D; Hu D; Huntsman S; Steele L; Patrick CS; Tao S; Hernandez N; Adams CD; Fejerman L; Gardner K; Nápoles AM; Pérez-Stable EJ; Weitzel JN; Bengtsson H; Huang FW; Neuhausen SL; Ziv E
Cancer Res; 2023 Aug; 83(15):2600-2613. PubMed ID: 37145128
[TBL] [Abstract] [Full Text] [Related]
12. Giant juvenile fibroadenomas with and without prominent pseudoangiomatous stromal hyperplasia (PASH)-like change: clinicopathological and molecular characteristics.
Jorns JM; Farooq A; Puzyrenko A; Jarzembowski J; Thike AA; Nasir NDM; Ng CCY; Liu W; Lee JY; Lim AH; Guan P; Teh BT; Tan PH
Histopathology; 2023 Sep; 83(3):357-365. PubMed ID: 37140543
[TBL] [Abstract] [Full Text] [Related]
13. Early Triple-Negative breast cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression.
Yeong J; Goh D; Tan TJ; Tan B; Sivaraj H; Koh V; Tatt Lim JC; Joseph CR; Ye J; Yong Tay TK; Chan Lau M; Chan JY; Ng C; Iqbal J; Teh BT; Dent RA; Tan PH
Mod Pathol; 2023 Apr; 36(4):100056. PubMed ID: 36788078
[TBL] [Abstract] [Full Text] [Related]
14. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Luen SJ; Viale G; Nik-Zainal S; Savas P; Kammler R; Dell'Orto P; Biasi O; Degasperi A; Brown LC; Láng I; MacGrogan G; Tondini C; Bellet M; Villa F; Bernardo A; Ciruelos E; Karlsson P; Neven P; Climent M; Müller B; Jochum W; Bonnefoi H; Martino S; Davidson NE; Geyer C; Chia SK; Ingle JN; Coleman R; Solbach C; Thürlimann B; Colleoni M; Coates AS; Goldhirsch A; Fleming GF; Francis PA; Speed TP; Regan MM; Loi S
Ann Oncol; 2023 Apr; 34(4):397-409. PubMed ID: 36709040
[TBL] [Abstract] [Full Text] [Related]
15. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry.
Mueller SH; Lai AG; Valkovskaya M; Michailidou K; Bolla MK; Wang Q; Dennis J; Lush M; Abu-Ful Z; Ahearn TU; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Aronson KJ; Augustinsson A; Baert T; Freeman LEB; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Blomqvist C; Bogdanova NV; Bojesen SE; Bonanni B; Brenner H; Brucker SY; Buys SS; Castelao JE; Chan TL; Chang-Claude J; Chanock SJ; Choi JY; Chung WK; ; Colonna SV; ; Cornelissen S; Couch FJ; Czene K; Daly MB; Devilee P; Dörk T; Dossus L; Dwek M; Eccles DM; Ekici AB; Eliassen AH; Engel C; Evans DG; Fasching PA; Fletcher O; Flyger H; Gago-Dominguez M; Gao YT; García-Closas M; García-Sáenz JA; Genkinger J; Gentry-Maharaj A; Grassmann F; Guénel P; Gündert M; Haeberle L; Hahnen E; Haiman CA; Håkansson N; Hall P; Harkness EF; Harrington PA; Hartikainen JM; Hartman M; Hein A; Ho WK; Hooning MJ; Hoppe R; Hopper JL; Houlston RS; Howell A; Hunter DJ; Huo D; ; Ito H; Iwasaki M; Jakubowska A; Janni W; John EM; Jones ME; Jung A; Kaaks R; Kang D; Khusnutdinova EK; Kim SW; Kitahara CM; Koutros S; Kraft P; Kristensen VN; Kubelka-Sabit K; Kurian AW; Kwong A; Lacey JV; Lambrechts D; Le Marchand L; Li J; Linet M; Lo WY; Long J; Lophatananon A; Mannermaa A; Manoochehri M; Margolin S; Matsuo K; Mavroudis D; Menon U; Muir K; Murphy RA; Nevanlinna H; Newman WG; Niederacher D; O'Brien KM; Obi N; Offit K; Olopade OI; Olshan AF; Olsson H; Park SK; Patel AV; Patel A; Perou CM; Peto J; Pharoah PDP; Plaseska-Karanfilska D; Presneau N; Rack B; Radice P; Ramachandran D; Rashid MU; Rennert G; Romero A; Ruddy KJ; Ruebner M; Saloustros E; Sandler DP; Sawyer EJ; Schmidt MK; Schmutzler RK; Schneider MO; Scott C; Shah M; Sharma P; Shen CY; Shu XO; Simard J; Surowy H; Tamimi RM; Tapper WJ; Taylor JA; Teo SH; Teras LR; Toland AE; Tollenaar RAEM; Torres D; Torres-Mejía G; Troester MA; Truong T; Vachon CM; Vijai J; Weinberg CR; Wendt C; Winqvist R; Wolk A; Wu AH; Yamaji T; Yang XR; Yu JC; Zheng W; Ziogas A; Ziv E; Dunning AM; Easton DF; Hemingway H; Hamann U; Kuchenbaecker KB
Genome Med; 2023 Jan; 15(1):7. PubMed ID: 36703164
[TBL] [Abstract] [Full Text] [Related]
16. Crosstalk of three novel types of programmed cell death defines distinct microenvironment characterization and pharmacogenomic landscape in breast cancer.
Xu L
Front Immunol; 2022; 13():942765. PubMed ID: 36032140
[TBL] [Abstract] [Full Text] [Related]
17. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in breast cancer.
Stella S; Vitale SR; Massimino M; Motta G; Longhitano C; Lanzafame K; Martorana F; Fazzari C; Vecchio GM; Tirrò E; Inzerilli N; Carciotto R; Manzella L; Caruso M; Vigneri P
Cancer Genomics Proteomics; 2022; 19(4):464-476. PubMed ID: 35732329
[TBL] [Abstract] [Full Text] [Related]
18. Heritable genomic diversity in breast cancer driver genes and associations with risk in a Chilean population.
Morales-Pison S; Gonzalez-Hormazabal P; Tapia JC; Salas-Burgos A; Ampuero S; Gómez F; Waugh E; Reyes JM; Jara L
Biol Res; 2022 May; 55(1):20. PubMed ID: 35637532
[TBL] [Abstract] [Full Text] [Related]
19. Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis.
Guan Y; Shen G; Fang Q; Xin Y; Huo X; Li J; Zhao F; Ren D; Liu Z; Li Z; Zhao J
Clin Exp Med; 2023 Jun; 23(2):245-254. PubMed ID: 35304677
[TBL] [Abstract] [Full Text] [Related]
20. Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.
Asleh K; Negri GL; Spencer Miko SE; Colborne S; Hughes CS; Wang XQ; Gao D; Gilks CB; Chia SKL; Nielsen TO; Morin GB
Nat Commun; 2022 Feb; 13(1):896. PubMed ID: 35173148
[TBL] [Abstract] [Full Text] [Related]
[Next]
